|
|
Vaccine Detail
|
MEDI-534 |
| Vaccine Information |
- Vaccine Name: MEDI-534
- Target Pathogen: Parainfluenza virus
- Type: Live, attenuated vaccine
- Status: Research
- Host Species for Licensed Use: Hamster
- HN
gene engineering:
- Type: Recombinant protein preparation
- Description: Expresses the hPIV3 fusion (F) protein (Gomez et al., 2009)
- Detailed Gene Information: Click Here.
- HN
gene engineering:
- Type: Recombinant protein preparation
- Description: Expresses the hPIV3 hemagglutinin-neuraminidase (Gomez et al., 2009)
- Detailed Gene Information: Click Here.
- HN
gene engineering:
- Type: Recombinant protein preparation
- Description: Expresses the hPIV3 F proteins from the bPIV3 viral genome.(Gomez et al., 2009)
- Detailed Gene Information: Click Here.
- Preparation: Vaccine virus was recovered from Vero cells using plasmid rescue procedure and was further expanded in Vero cells as previously described by Tang et al. AccuSpray sprayers were filled with a 0.2 mL single intranasal dose of MEDI-534 containing 10^4, 10^5, or 10^6 median tissue culture infectious dose (Gomez et al., 2009)
- Immunization Route: intranasal immunization
- Approved Age for Licensed Use: 1 to 9 year old children
- Description: MEDI-534 is a live, attenuated, intranasal vaccine against RSV and PIV3. It is a chimeric bovine/human (b/h) PIV3 construct that expresses the hPIV3 fusion (F), the hPIV3 hemagglutinin-neuraminidase, and the RSV F proteins from a bPIV3 viral genome. (Gomez et al., 2009)
|
| Host Response |
|
|
| References |
|
|
|
